Skip to content
Pharma
Bioequivalence Studies
Pharmaceutical Equivalence
Analytical Services
Development and validation of assays for content,
impurities and residual solvents
Solubility and dissolution for R&D
Stability study (physicochemical analysis)
Forced degradation (compliance with RDC 53/2015)
Extractables and leachables study (analysis)
Elemental impurities USP-NF <232>/<233> and ICH Q3D
Nitrosamines Study (Phase 2)
Clinical Research Center Phase I to IV
CRO Services
Regulatory Affairs
Medical Writing
Management of Phase I to IV Studies
Clinical Monitoring
Biostatistics
Central Laboratory
Toxicology
Diagnostics
Software
About Us
Who We Are
Our Structure
Careers
Blog
Pharma
Bioequivalence Studies
Pharmaceutical Equivalence
Analytical Services
Development and validation of assays for content,
impurities and residual solvents
Solubility and dissolution for R&D
Stability study (physicochemical analysis)
Forced degradation (compliance with RDC 53/2015)
Extractables and leachables study (analysis)
Elemental impurities USP-NF <232>/<233> and ICH Q3D
Nitrosamines Study (Phase 2)
Clinical Research Center Phase I to IV
CRO Services
Regulatory Affairs
Medical Writing
Management of Phase I to IV Studies
Clinical Monitoring
Biostatistics
Central Laboratory
Toxicology
Diagnostics
Software
About Us
Who We Are
Our Structure
Careers
Blog
EN
PT
ES
Contact Us
EN
PT
ES
Pharma
Bioequivalence Studies
Pharmaceutical Equivalence
Analytical Services
Development and validation of assays for content,
impurities and residual solvents
Solubility and dissolution for R&D
Stability study (physicochemical analysis)
Forced degradation (compliance with RDC 53/2015)
Extractables and leachables study (analysis)
Elemental impurities USP-NF <232>/<233> and ICH Q3D
Nitrosamines Study (Phase 2)
Clinical Research Center Phase I to IV
CRO Services
Regulatory Affairs
Medical Writing
Management of Phase I to IV Studies
Clinical Monitoring
Biostatistics
Central Laboratory
Toxicology
Diagnostics
Software
About Us
Who We Are
Our Structure
Careers
Blog
Pharma
Bioequivalence Studies
Pharmaceutical Equivalence
Analytical Services
Development and validation of assays for content,
impurities and residual solvents
Solubility and dissolution for R&D
Stability study (physicochemical analysis)
Forced degradation (compliance with RDC 53/2015)
Extractables and leachables study (analysis)
Elemental impurities USP-NF <232>/<233> and ICH Q3D
Nitrosamines Study (Phase 2)
Clinical Research Center Phase I to IV
CRO Services
Regulatory Affairs
Medical Writing
Management of Phase I to IV Studies
Clinical Monitoring
Biostatistics
Central Laboratory
Toxicology
Diagnostics
Software
About Us
Who We Are
Our Structure
Careers
Blog
Contact Us
Synvia Blog
News, trends and expert insights for you.
Receive content and updates with priority.
Register
